World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
108
Citations
40439
World Ranking
6034
National Ranking
3225

John T. Isaacs publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John T. Isaacs sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 398 publications — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

John T. Isaacs D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John T. Isaacs sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 108 D-Index — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

John T. Isaacs is affiliated with Johns Hopkins University in the United States and has a research focus primarily in Medicine and Biochemistry, Genetics and Molecular Biology. Their work spans several subfields including Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Cancer Research, and Genetics.

The scientist's research covers main topics such as Prostate Cancer Treatment and Research, Hormonal and Reproductive Studies, Estrogen and Related Hormone Effects, Radiopharmaceutical Chemistry and Applications, Epigenetics and DNA Methylation, Ubiquitin and Proteasome Pathways, and PARP Inhibition in Cancer Therapy.

Recent notable publications include:

  • Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress (2020, Cell Reports)
  • Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors (2020, Oncogene)
  • Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer (2021, JCI Insight)
  • Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy (2020, European Journal of Cancer)
  • Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC (2022, Journal of Clinical Investigation)

Their frequent coauthors include:

  • Samuel R. Denmeade
  • Peter S. Nelson
  • Angelo M. De Marzo
  • W. Nathaniel Brennen
  • Susan L. Dalrymple

John T. Isaacs has published extensively in several venues. The most frequent publication venues are:

  • The Prostate
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Oncogene
  • Cancer Research
  • Molecular Cancer Therapeutics

Best Publications

  • AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

    Emmanuel S. Antonarakis;Changxue Lu;Hao Wang;Brandon Luber

  • KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2.

    Jin-Tang Dong;P. W. Lamb;C. W. Rinker-Schaeffer;J. Vukanovic

  • Activation of programmed cell death in the rat ventral prostate after castration.

    Natasha Kyprianou;John T. Isaacs

  • Etiology and disease process of benign prostatic hyperplasia

    John Tod Isaacs;Donald S. Coffey

  • A history of prostate cancer treatment

    Samuel R. Denmeade;John T. Isaacs

  • Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene

    B. Levine;Qi Huang;J. T. Isaacs;J. C. Reed

  • Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation.

    Natasha Kyprianou;Hugh F. English;John T. Isaacs

  • Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer.

    Samuel R. Denmeade;Xiaohui S. Lin;John T. Isaacs

  • Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation.

    Natasha Kyprianou;Hugh F. English;Nancy E. Davidson;John T. Isaacs

  • Establishment and Characterization of Seven Dunning Rat Prostatic Cancer Cell Lines and Their Use in Developing Methods for Predicting Metastatic Abilities of Prostatic Cancers

    J.T. Isaacs;J.T. Isaacs;W.B. Isaacs;W.B. Isaacs;W.F.J. Feitz;W.F.J. Feitz;J. Scheres;J. Scheres

  • Adaptation versus Selection as the Mechanism Responsible for the Relapse of Prostatic Cancer to Androgen Ablation Therapy as Studied in the Dunning R-3327-H Adenocarcinoma

    John T. Isaacs;Donald S. Coffey

  • Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death

    Natasha Kyprianou;John T. Isaacs

  • Antagonistic Effect of Androgen on Prostatic Cell Death

    J.T. Isaacs

  • Implication of cell kinetic changes during the progression of human prostatic cancer

    Richard R. Berges;Richard R. Berges;Jasminka Vukanovic;Jonathan I. Epstein;Marne CarMichel

  • Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss

    J T Dong;H Suzuki;S S Pin;G S Bova

  • The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin.

    Yuzo Furuya;Per Lundmo;Per Lundmo;Alison D. Short;Donald L. Gill

  • The biology of hormone refractory prostate cancer. Why does it develop

    John T. Isaacs

  • Prostate-Specific Antigen-Activated Thapsigargin Prodrug as Targeted Therapy for Prostate Cancer

    Samuel R. Denmeade;Carsten M. Jakobsen;Samuel Janssen;Saeed R. Khan

  • Clinical evidence for and implications of the multistep development of prostate cancer.

    H. Ballentine Carter;Steven Piantadosi;John T. Isaacs

  • Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration.

    Hugh F. English;Natasha Kyprianou;John T. Isaacs

Frequent Co-Authors

William B. Isaacs
William B. Isaacs Johns Hopkins University
Angelo M. De Marzo
Angelo M. De Marzo Johns Hopkins University School of Medicine
Michael A. Carducci
Michael A. Carducci Johns Hopkins University
Emmanuel S. Antonarakis
Emmanuel S. Antonarakis University of Minnesota
Alan K. Meeker
Alan K. Meeker Johns Hopkins University School of Medicine
J. Carl Barrett
J. Carl Barrett AstraZeneca (United Kingdom)
Jack A. Schalken
Jack A. Schalken Radboud University
Peter S. Nelson
Peter S. Nelson Fred Hutchinson Cancer Research Center
Bertrand Tombal
Bertrand Tombal Université Catholique de Louvain
Jeffrey M. Karp
Jeffrey M. Karp Brigham and Women's Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine opens opportunities beyond becoming a traditional doctor. Whether your interests lie in healthcare management, advanced nursing, or pharmacy, there are diverse degree pathways available—many of which can be pursued online for added flexibility.

For those interested in leadership and operational roles, earning a health administration degree online is a popular route. These programs equip students with the skills needed to manage hospitals and healthcare systems efficiently.

Cost is a major factor for many prospective students. Understanding mha degree cost can help you make informed decisions about your educational investment.

Nursing professionals looking to achieve the highest level of clinical practice are exploring the cheapest online bsn to dnp programs. These accelerated programs allow nurses to advance their credentials with greater affordability.

Finally, aspiring pharmacists can pursue their passion through online options as well. Comparing online pharmacy school cost helps students identify programs that fit their budget and career goals.

Best Scientists Citing John T. Isaacs

Trending Scientists

Recently Published Articles